China Resources Sanjiu Medical & Pharmaceutical

Traditional Chinese medicine manufacturer

000999 · SZSE · China

Public Market Listing

000999SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for China Resources Sanjiu Medical & Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
GLP-1/GIP receptor (dual)Peptide
ObesityType 2 Diabetes
Shenfu injection(Shenfu Zhusheye)
Preclinical / Unstaged
Multi-target (ginsenoside)Botanical
Heart Failure

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
BGM0504Phase 2Overweight or Obese Participants Without Diabetes
Est. primary completion 2027-02-28 · NCT07658560 · CT.gov ↗
What to watch
April 2027 (1)
BGM0504Phase 3Type 2 Diabetes (T2DM)
Est. primary completion 2027-04-30 · NCT07064486 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
BGM0504Phase 3Type 2 Diabetes (T2DM)
Est. primary completion 2028-09-30 · NCT07743983 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 June 2026Filing acceptedBGM0504NMPA CDE accepts the BGM0504 injection NDA for weight management
CN, NMPA · BrightGene Pharmaceutical (Suzhou) Co., Ltd. (BrightGene subsidiary) · Source ↗
7 May 2026Topline resultBGM0504BGM0504 Phase III topline positive in overweight or obesity
BrightGene Bio-Medical · Source ↗

Financial reports

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$4.4B$241M$666M—report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.8B$133M$687M—report ↗
2023-FY$3.5B———report ↗